JP2010090119A - Ophthalmic solution for silicone hydrogel contact lens - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an ophthalmic solution for silicone hydrogel contact lenses, effectively inhibiting the discoloration (yellowing) of a silicone hydrogel contact lens, when the lens is brought into contact with ketotifen and/or its salt. <P>SOLUTION: There is provided the ophthalmic solution for the silicone hydrogel contact lenses, comprising (A) at least one selected from the group consisting of ketotifen and its salts and (B) at least one selected from the group consisting of amino acids, taurine and their salts. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to an ophthalmic solution capable of suppressing yellowing (yellowing) of a silicone hydrogel contact lens that occurs when ketotifen and / or a salt thereof and a silicone hydrogel contact lens are brought into contact with each other. The present invention also relates to a method for suppressing discoloration (yellowing) of a silicone hydrogel contact lens caused by ketotifen and / or a salt thereof, and a method for imparting an action of suppressing the discoloration (yellowing) to an eye drop. The present invention also relates to an agent for suppressing discoloration (yellowing) of a silicone hydrogel contact lens caused by contacting ketotifen and / or a salt thereof. Furthermore, the present invention relates to a method for screening a discoloration suppressing substance capable of suppressing the discoloration (yellowing).

  Furthermore, the present invention relates to a method for suppressing the adhesion of corneal cells to the surface of a nonionic silicone hydrogel contact lens.

  In recent years, the number of wearers of contact lenses (CL) has increased, and in particular, the number of wearers of soft contact lenses (SCL) has increased. In general, it has been pointed out that when a soft contact lens is worn, the amount of oxygen supplied from the atmosphere decreases, which may result in suppression of corneal epithelial cell division and thickening of the cornea. Therefore, development of soft contact lenses having higher oxygen permeability has been advanced.

  Under such circumstances, silicone hydrogel contact lenses have been developed in recent years as soft contact lenses having high oxygen permeability. Silicone hydrogel contact lenses achieve oxygen permeability several times that of conventional hydrogel contact lenses by blending silicone with hydrogel. Therefore, it is highly expected that the oxygen supply shortage, which is a weak point of the soft contact lens, can be improved and the adverse effects on the cornea due to the oxygen shortage can be greatly suppressed.

  In general, it is indispensable to design eye drops to be applied to the eyes of a soft contact lens wearer, taking into account the safety and other effects according to the type of soft contact lens. In particular, since soft contact lenses are made of different materials, it is important that eye drops applied to the eyes of a soft contact lens wearer are designed according to the properties of the applied soft contact lens.

  On the other hand, ketotifen and its salts are used in eye drops for the purpose of imparting an antiallergic effect (see Patent Document 1-2), but the influence of these components on the color tone of silicone hydrogel contact lenses is clear. Not been. Moreover, the current situation is that even the influence of the combined use of ketotifen and / or a salt thereof and an amino acid, taurine, and / or a salt thereof on the color tone of the silicone hydrogel contact lens cannot be estimated.

JP 2004-175771 A JP 2004-315365 A

  The present inventor has conducted various studies on various soft contact lenses and has not anticipated at all. For silicone hydrogel contact lenses (hereinafter sometimes abbreviated as SHCL), ketotifen and The present inventors have obtained a completely new finding that when an eye drop containing a salt thereof is applied, the lens undergoes significant yellowing due to a chemical change that is not observed when applied to other soft contact lenses. Such a chemical change of significant yellowing of the lens not only causes anxiety and discomfort to the lens user, but also may change the field of vision of the lens wearer, and in turn wears a yellowed lens. By continuing to do so, there is also a risk of causing serious problems such as decreased visual acuity. In addition, wearing a yellowed lens causes a change in the color tone of the wearer's eyes (particularly the color tone of the white eye), which may affect the impression of the wearer.

  Therefore, SHCL eye drops that can effectively suppress the discoloration (yellowing) of SHCL that occurs when ketotifen and / or a salt thereof are brought into contact with SHCL, in particular, ketotifen and / or can be instilled during SHCL wearing. Development of an eye drop containing ketotifen and / or a salt thereof that can suppress discoloration of SHCL caused by the salt is demanded.

  As a result of intensive studies to solve the above problems, the present inventor has found that, in addition to ketotifen and / or a salt thereof, when amino acids, taurine, and / or a salt thereof are used in combination, ketotifen and / or a salt thereof It has been found that the discoloration (yellowing) of SHCL that occurs when brought into contact with SHCL can be remarkably suppressed. Furthermore, as a result of investigations, the present inventor has found that when ketotifen and / or a salt thereof are used in combination with an amino acid, taurine, and / or a salt thereof, a nonionic silicone hydrogel contact lens (hereinafter referred to as a nonionic silicone). It was also found that the adhesion of corneal cells to the surface can be synergistically suppressed (sometimes abbreviated as SHCL). The present invention has been completed by further studies based on this finding.

That is, this invention provides the eye drop for silicone hydrogel contact lenses listed below.
Item 1. (A) Silicone hydrolyzate containing at least one selected from the group consisting of ketotifen and salts thereof, and (B) at least one amino acid selected from the group consisting of amino acids, taurine, and salts thereof Eye drops for gel contact lenses.
Item 2. Item 5. The eye drop for a silicone hydrogel contact lens according to Item 1, comprising ketotifen fumarate as the component (A).
Item 3. Item 3. The eye drop for a silicone hydrogel contact lens according to Item 1 or 2, comprising as component (B) at least one selected from the group consisting of ε-aminocaproic acid, aspartic acid, taurine and salts thereof.
Item 4. Item 4. The eye drop for a silicone hydrogel contact lens according to any one of Items 1 to 3, further comprising (C) a chloride ion.
Item 5. Item 5. An eye drop for a silicone hydrogel contact lens according to any one of Items 1 to 4, further comprising (E) an isotonic agent.
Item 6. Item 6. The eye drop for a silicone hydrogel contact lens according to any one of Items 1 to 5, further comprising (G) a buffer.
Item 7. Item 7. The eye drop for a silicone hydrogel contact lens according to any one of Items 1 to 6, wherein the blending ratio of the component (A) is 0.01 w / v% or more.
Item 8. Item 8. The eye drop for a silicone hydrogel contact lens according to any one of Items 1 to 7, wherein the blending ratio of the component (B) is 0.005 w / v% or more.
Item 9. Item 9. The eye drop for a silicone hydrogel contact lens according to any one of Items 1 to 8, wherein the silicone hydrogel contact lens is ionic.
Item 10. Item 10. The eye drop for a silicone hydrogel contact lens according to any one of Items 1 to 9, wherein the silicone hydrogel contact lens is a lens that has been surface-treated by oxygen plasma treatment.
Item 11. The silicone hydrogel contact lens is a lens made of a copolymer comprising at least one silicon-containing monomer selected from the group consisting of a silicon-containing vinyl carbamate monomer and a silicon-containing vinyl carbonate monomer, and a hydrophilic monomer. Eye drops for silicone hydrogel contact lenses according to any one of 1 to 10.
Item 12. Item 12. The silicone hydrogel contact lens according to Item 11, wherein the silicone hydrogel contact lens is a lens made of a copolymer containing tris (trimethylsiloxane) silylpropylvinylcarbamate and N-vinyl-2-pyrrolidone as constituent monomers. Eye drops for use.
Item 13. Item 13. The ophthalmic solution for silicone hydrogel contact lenses according to any one of Items 1 to 12, wherein the silicone hydrogel contact lens is a lens having an oxygen permeability of greater than 80 Dk / L.
Item 14. Item 14. The eye drop for a silicone hydrogel contact lens according to any one of Items 1 to 13, wherein the silicone hydrogel contact lens is a lens having a water content of 20% or more.
Item 15. Item 9. The eye drop for a silicone hydrogel contact lens according to any one of Items 1 to 8, wherein the silicone hydrogel contact lens is nonionic.
Moreover, this invention provides the method of giving the effect | action which suppresses discoloration (yellowing) of a silicone hydrogel contact lens to the eyedrops, and the method of suppressing discoloration (yellowing) of the silicone hydrogel contact lens hung up below.
Item 16. (A) at least one selected from the group consisting of ketotifen and salts thereof and (B) at least one amino acid selected from the group consisting of amino acids, taurine and salts thereof, A method for suppressing discoloration of a silicone hydrogel contact lens caused by contacting the component (A).
Item 17. (A) An eye drop for a silicone hydrogel contact lens containing at least one selected from the group consisting of ketotifen and salts thereof, and (B) at least one selected from the group consisting of amino acids, taurine, and salts thereof A method of imparting to the eye drops an action of suppressing discoloration of a silicone hydrogel contact lens produced by contacting the component (A), comprising mixing various amino acids.
Moreover, this invention provides the discoloration (yellowing) inhibitor listed below.
Item 18. (B) containing at least one amino acid selected from the group consisting of amino acids, taurine, and salts thereof, and (A) contacting at least one selected from the group consisting of ketotifen and salts thereof Agent for suppressing discoloration of the resulting silicone hydrogel contact lens.
Furthermore, this invention provides the screening method of the discoloration (yellowing) inhibitory substance hung up below.
Item 19. A method for screening a discoloration inhibitor capable of suppressing discoloration of a silicone hydrogel contact lens produced by contacting at least one selected from the group consisting of ketotifen and a salt thereof,
(a) preparing a test solution containing at least one selected from the group consisting of ketotifen and a salt thereof and a test substance;
(b) contacting the test solution with a silicone hydrogel contact lens and measuring the degree of discoloration of the silicone hydrogel contact lens; and
(c) selecting a test solution in which suppression of discoloration of the silicone hydrogel contact lens is observed, and selecting a test substance contained in the test solution as the discoloration suppressing substance,
A screening method comprising:
The present invention also provides a method for inhibiting corneal epithelial cell adhesion to nonionic silicone hydrogel contact lenses, and a method for imparting corneal epithelial cell adhesion inhibiting action to nonionic silicone hydrogel contact lenses to eye drops as described below. I will provide a.
Item 20. An eye drop containing at least one selected from the group consisting of (A) ketotifen and a salt thereof and (B) at least one selected from the group consisting of an amino acid, taurine and a salt thereof; A method for suppressing adhesion of corneal epithelial cells to a nonionic silicone hydrogel contact lens, comprising contacting the silicone hydrogel contact lens.
Item 21. The eye drops for nonionic silicone hydrogel contact lenses are selected from the group consisting of (A) amino acids, taurine, and salts thereof, together with at least one selected from the group consisting of (A) ketotifen and salts thereof At least 1 sort (s) is mix | blended, The method to provide the effect | action which suppresses adhesion | attachment of the corneal epithelial cell with respect to a nonionic silicone hydrogel contact lens to this eye drop.
Item 22. (B) An eye drop for a nonionic silicone hydrogel contact lens containing at least one selected from the group consisting of amino acids, taurine, and salts thereof, (A) selected from the group consisting of ketotifen and salts thereof A method for imparting to the eye drop an action of suppressing adhesion of corneal epithelial cells to a nonionic silicone hydrogel contact lens, comprising blending at least one of the above.

  According to the eye drop for SHCL of the present invention, since it contains ketotifen and / or a salt thereof, discoloration (yellowing) of SHCL that occurs when ketotifen and / or a salt thereof and SHCL are brought into contact can be suppressed. In addition, it does not cause a decrease in visual acuity for SHCL wearers, does not cause inconvenience in appearance and discomfort, etc., and safely enjoys the antiallergic effect of ketotifen and / or its salts. Can be made. Furthermore, the amino acids contained in the eye drops for SHCL of the present invention have not only an action of suppressing discoloration (yellowing) of SHCL but also an action of accelerating cell respiration in the ocular mucosa and reducing eye strain. Since it exhibits, the eye drop for SHCL of the present invention is also effective in improving eye strain.

  Furthermore, since the screening method of the present invention makes it possible to obtain a discoloration-inhibiting substance that can suppress discoloration (yellowing) of SHCL caused by ketotifen and / or a salt thereof, including ketotifen and / or a salt thereof, It is useful for the development of eye drops in which discoloration (yellowing) of the SHCL is suppressed even when used during SHCL wearing.

  In addition, it has been clarified by the present inventors that nonionic SHCL has a characteristic characteristic that corneal cells are remarkably easy to adhere, but according to the eye drop for SHCL of the present invention, nonionic Can effectively inhibit corneal cell adhesion to sex SHCL. Therefore, according to the present invention, it is possible to wear nonionic SHCL with high safety in that adhesion of corneal cells to nonionic SHCL can be suppressed.

In the reference test example 1, it is a figure which shows the result of having examined the influence which ketotifen fumarate has with respect to the color tone of SCL. In the reference test example 1, it is a figure which shows the result of having examined the influence which ketotifen fumarate exerts on the color tone of SHCL. In the reference test example 2, it is a figure which shows the result of having examined the influence of the buffering agent with respect to the yellowing of SHCL which arises with ketotifen fumarate. In Test Example 1, it is a figure which shows the result of having evaluated the effect ((DELTA) E * ab) which suppresses the yellowing of SHCL produced with the ketotifen fumarate of a test liquid (Examples 1-4 and Comparative Examples 1-2). In the reference test example 3, it is a figure which shows the result of having evaluated the adhesiveness of the corneal epithelial cell of various soft contact lenses. In Test Example 2, it is a figure which shows the result of having evaluated the corneal epithelial cell adhesion inhibitory effect with respect to nonionic SHCL of a test liquid (Example 5-6 and Comparative Example 3-5).

(I) SHCL eye drops The SHCL eye drops of the present invention contain at least one selected from the group consisting of ketotifen and a salt thereof (hereinafter also referred to as component (A)). Ketotifen is a compound also referred to as 4,9-dihydro-4- (1-methyl-4-piperidylidene) -10H-benzo [4,5] cyclohepta [1,2-b] thiophen-10-one. Ketotifen and its salts are known compounds as antiallergic agents, and may be synthesized by known methods or obtained as commercial products.

  Among the components (A) used in the present invention, the salt of ketotifen is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Organic acid salts [eg, monocarboxylate (acetate, trifluoroacetate, butyrate, palmitate, stearate, etc.), polyvalent carboxylate (fumarate, maleate, succinate, etc. Acid salt, malonate, etc.), oxycarboxylate (lactate, tartrate, citrate, etc.), organic sulfonate (methanesulfonate, toluenesulfonate, tosylate, etc.)], inorganic Acid salts (eg, hydrochloride, sulfate, nitrate, hydrobromide, phosphate, etc.), salts with organic bases (eg, methylamine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, tripyridine , Salts with organic amines such as picoline), salts with inorganic bases [for example, ammonium salts; alkali metals (sodium, potassium, etc.), alkaline earth metals (calcium, magnesium, etc.), salts with metals such as aluminum, etc. Etc.]. Among these salts, an organic acid salt and / or an inorganic acid salt, preferably an organic acid salt, more preferably a polyvalent carboxylate, still more preferably a fumarate and / or maleate, particularly preferably Includes fumarate. These ketotifen salts may be used alone or in any combination of two or more.

  In the eye drops for SHCL of the present invention, as the component (A), one kind of ketotifen and a salt thereof may be selected and used alone, or two or more kinds may be arbitrarily combined. May be used. The component (A) used in the present invention is preferably a salt of ketotifen, more preferably an organic acid salt and / or inorganic acid salt of ketotifen, more preferably an organic acid salt of ketotifen, and still more preferably a polyvalent carboxylic acid of ketotifen. Further preferred are ketotifen fumarate and / or maleate, particularly preferably ketotifen fumarate (ketotifen fumarate).

  In the eye drop for SHCL of the present invention, the blending ratio of the component (A) is appropriately set according to the type of the component (A), the type of other blending components, etc., as an example, The total amount of the component (A) is 0.01 w / v% or more, preferably 0.01-1 w / v%, more preferably 0.02-0.7 w / v%, still more preferably 0. 0.03-0.5 w / v%, particularly preferably 0.05-0.1 w / v%.

  Furthermore, the eye drop for SHCL of the present invention may be expressed as at least one selected from the group consisting of amino acids, taurine and salts thereof (hereinafter referred to as component (B), in addition to component (A) above. ). By blending the component (B) in this way, it becomes possible to effectively suppress the discoloration (yellowing) of SHCL caused by the component (A), and the corneal epithelium for nonionic silicone hydrogel contact lenses. Cell adhesion can be more effectively suppressed.

  Of the above-mentioned component (A) used in the present invention, the amino acid is not particularly limited as long as it is pharmacologically (pharmaceutically) or physiologically acceptable. Any amino acid may be used. Specific examples of amino acids used in the present invention include ε-aminocaproic acid, glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, cysteine, cystine, γ-aminobutyric acid, asparagine, glutamine, Examples include serine, threonine, tyrosine, creatine, glutamic acid, aspartic acid, lysine, arginine, histidine, ornithine and the like. Among these amino acids, ε-aminocaproic acid and aspartic acid are preferable. These amino acids may be used alone or in any combination of two or more.

  Of the component (A) used in the present invention, taurine is a compound known as aminoethylsulfonic acid.

  The amino acid used as the component (A) in the present invention may be any of L-form, D-form and DL-form, but is preferably L-form.

  The salt of amino acid and / or taurine used as component (B) is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Specifically, organic acid salts [for example, monocarboxylate (acetate, trifluoroacetate, butyrate, palmitate, stearate, etc.), polyvalent carboxylate (fumarate, Maleate, succinate, malonate, etc.), oxycarboxylate (lactate, tartrate, citrate, etc.), organic sulfonate (methanesulfonate, toluenesulfonate, tosylate, etc.) ), Etc.], inorganic acid salts (eg, hydrochloride, sulfate, nitrate, hydrobromide, phosphate, etc.), salts with organic bases (eg, methylamine, triethylamine, triethanolamine, morpholine, piperazine) The Salts with organic amines such as lysine, tripyridine and picoline), salts with inorganic bases [eg ammonium salts; alkali metals (sodium, potassium, etc.), alkaline earth metals (calcium, magnesium, etc.), metals such as aluminum Etc.] and the like. Among these salts, preferred are salts with inorganic bases, more preferred are alkali metal salts and alkaline earth metal salts, and still more preferred are magnesium salts and potassium salts. These salts may be used alone or in any combination of two or more.

  In the eye drop for SHCL of the present invention, as the component (B), one type of amino acid, taurine, and salts thereof may be selected and used alone, or two or more types may be used. Any combination may be used.

  Among the components (B), from the viewpoint of more effectively suppressing discoloration of SHCL caused by the component (A), preferably ε-aminocaproic acid, aspartic acid, taurine, and salts thereof; more preferably , Ε-aminocaproic acid, taurine, potassium aspartate, and magnesium potassium aspartate. The component (B) exemplified here is also preferable from the viewpoint of more effectively suppressing adhesion of corneal epithelial cells to nonionic SHCL.

  In the eye drop for SHCL of the present invention, the blending ratio of the component (B) is appropriately set according to the type of the component (B), the type of other blending components, etc., as an example, The total amount of the component (B) is 0.005 w / v% or more, preferably 0.005 to 10 w / v%, more preferably 0.01 to 5 w / v%, still more preferably 0.05 to Examples are 2 w / v%, particularly preferably 0.1 to 1 w / v%.

  In the eye drop for SHCL of the present invention, the ratio of the component (B) to the component (A) is not particularly limited as long as the above-described blending ratio is satisfied, but the SHCL resulting from the component (A) From the viewpoint of more effectively suppressing discoloration, the total amount of the component (B) is 10 to 8000 parts by weight, preferably 50 to 4000 parts by weight, more preferably, per 100 parts by weight of the total amount of the component (A). It is desirable to satisfy the ratio of 100 to 2000 parts by weight. Such a ratio is also suitable from the viewpoint of effectively suppressing adhesion of corneal epithelial cells to nonionic SHCL.

  Furthermore, the eye drop for SHCL of the present invention preferably contains chloride ions in addition to the components (A) and (B). Thus, by including chloride ions, the effect of the present invention that suppresses the discoloration of SHCL caused by the component (A) can be more reliably obtained.

  In order to contain the chloride ion in the eye drops for SHCL of the present invention, a compound that liberates the chloride ion in an aqueous solution may be added. The compound that releases chloride ion in an aqueous solution is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. For example, an alkali metal such as sodium chloride or potassium chloride can be used. Chlorides; chlorides of alkaline earth metals such as magnesium chloride and calcium chloride; hydrochlorides of amino acids such as histidine hydrochloride, arginine hydrochloride, lysine hydrochloride; epinephrine hydrochloride, ephedrine hydrochloride, tetrahydrozoline hydrochloride, naphazoline hydrochloride, phenylephrine hydrochloride Dl-methylephedrine hydrochloride, berberine chloride, lysozyme chloride, diphenhydramine hydrochloride, benzalkonium chloride, benzethonium chloride, alkyldiaminoethylglycine hydrochloride, hydrochloric acid and the like. Among these, from the viewpoint of obtaining the effects of the present invention more reliably, alkali metal chlorides are preferable, sodium chloride and / or potassium chloride are more preferable, and sodium chloride is particularly preferable. These compounds that liberate chloride ions in an aqueous solution may be used alone or in any combination of two or more.

  When chloride ions are contained in the SHCL eyedrops of the present invention, the final content of chloride ions in the eyedrops can be appropriately set according to the type of compound from which chloride ions are derived. As an example of the final content ratio of chloride ions, the total amount of chloride ions with respect to the total amount of the eye drops is 15 to 1000 mM, preferably 30 to 200 mM, more preferably 50 to 150 mM. The As used herein, the “final content ratio of chloride ions” means that when the component (A) and / or (B) is in the form of a salt capable of liberating chloride ions, It means the sum of the content ratio of chloride ions derived from the component (B) and the content ratio of chloride ions derived from other compounds.

  The eye drop for SHCL of the present invention may further contain an isotonic agent. The isotonic agent that can be incorporated into the SHCL eye drops of the present invention is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Specific examples of such isotonic agents include, for example, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, sodium hydrogen sulfite, sodium sulfite, potassium chloride, calcium chloride, sodium chloride, magnesium chloride, acetic acid Examples include potassium, sodium acetate, sodium hydrogen carbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate, glycerin, propylene glycol and the like. Among these isotonic agents, potassium chloride, calcium chloride, sodium chloride, and magnesium chloride are expected to exert the effects of the present invention more reliably. Therefore, they are preferably used for the eye drops for SHCL of the present invention. Is done. These isotonic agents may be used alone or in any combination of two or more.

  When an isotonic agent is blended in the SHCL eyedrops of the present invention, the blending ratio of the isotonic agent differs depending on the type of tonicity agent used and cannot be uniformly defined. For example, the ratio by which the total amount of the tonicity agent is 0.01 to 10 w / v%, preferably 0.05 to 5 w / v%, more preferably 0.1 to 2 w / v% is exemplified.

  The eye drop for SHCL of the present invention may further contain a buffer. The buffer that can be incorporated into the eye drops for SHCL of the present invention is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Examples of such buffers include borate buffer, phosphate buffer, carbonate buffer, citrate buffer, acetate buffer, epsilon-aminocaproic acid, aspartic acid, aspartate and the like. These buffering agents may be used in combination. Preferred buffering agents are borate buffer, phosphate buffer, carbonate buffer, and citrate buffer, and particularly preferred buffers are borate buffer and phosphate buffer. Examples of the boric acid buffer include borates such as alkali metal borate and alkaline earth metal borate. Examples of the phosphate buffer include phosphates such as alkali metal phosphates and alkaline earth metal phosphates. Examples of the carbonate buffer include carbonates such as alkali metal carbonates and alkaline earth metal carbonates. Examples of the citrate buffer include alkali metal citrate and alkaline earth metal citrate. Moreover, you may use the borate or the hydrate of a phosphate as a borate buffer or a phosphate buffer. More specific examples include boric acid or a salt thereof (sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, borax, etc.), phosphoric acid or a salt thereof (disodium hydrogen phosphate, dihydrogen phosphate) Sodium, potassium dihydrogen phosphate, trisodium phosphate, dipotassium phosphate, calcium monohydrogen phosphate, calcium dihydrogen phosphate), carbonic acid or a salt thereof (sodium hydrogen carbonate, sodium carbonate, ammonium carbonate, potassium carbonate, Calcium carbonate, potassium hydrogen carbonate, magnesium carbonate, etc.), citric acid or a salt thereof (sodium citrate, potassium citrate, calcium citrate, sodium dihydrogen citrate, disodium citrate, etc.), acetic acid or a salt thereof (ammonium acetate) , Potassium acetate, calcium acetate, sodium acetate, etc.), asparagus Examples include formic acid or a salt thereof (sodium aspartate, magnesium aspartate, potassium aspartate, etc.). Among these buffering agents, phosphate buffering agents and boric acid buffering agents are preferably used for the SHCL eyedrops of the present invention because they are expected to exhibit the effects of the present invention more reliably. These buffering agents may be used alone or in any combination of two or more.

  When a buffering agent is blended in the SHCL eyedrops of the present invention, the blending ratio of the buffering agent varies depending on the type of buffering agent used, the type and amount of other blending components, the use of the eyedrops, etc. However, for example, the total amount of the buffer is 0.01 to 10 w / v%, preferably 0.1 to 5 w / v%, more preferably, with respect to the total amount of the eye drops. A ratio of 0.5 to 2 w / v% is exemplified.

  The eye drop for SHCL of the present invention may further contain a surfactant. The surfactant that can be blended in the eye drops for SHCL of the present invention is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable, and is a nonionic surfactant. , Any of amphoteric surfactants, anionic surfactants, and cationic surfactants may be used.

  Specific examples of the nonionic surfactant that can be blended in the eye drops for SHCL of the present invention include monolauric acid POE (20) sorbitan (polysorbate 20), monopalmitic acid POE (20) sorbitan (polysorbate 40), POE sorbitan fatty acid esters such as monostearic acid POE (20) sorbitan (polysorbate 60), tristearic acid POE (20) sorbitan (polysorbate 65), monooleic acid POE (20) sorbitan (polysorbate 80); POE / POP block copolymers such as poloxamer 235, poloxamer 188, poloxamer 403, poloxamer 237, poloxamer 124, etc .; POE cured castor oil such as POE (60) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 60); POE (9 POE alkyl ethers such as lauryl ether; POE-POP alkyl ethers such as POE (20) POP (4) cetyl ether; P POE alkylphenyl ethers such as OE (10) nonylphenyl ether are listed. In the compounds exemplified above, POE is polyoxyethylene, POP is polyoxypropylene, and the numbers in parentheses indicate the number of moles added. Specific examples of amphoteric surfactants that can be incorporated into the SHCL eye drops of the present invention include alkyldiaminoethylglycine. Specific examples of the cationic surfactant that can be incorporated into the SHCL eye drops of the present invention include benzalkonium chloride and benzethonium chloride. Examples of the anionic surfactant that can be blended in the eye drops for SHCL of the present invention include alkylbenzene sulfonate, alkyl sulfate, polyoxyethylene alkyl sulfate, and aliphatic α-sulfomethyl ester. And α-olefin sulfonic acid.

  In the eye drop for SHCL of the present invention, the above surfactants may be used alone or in combination of two or more.

  Among the above surfactants, preferably nonionic surfactants; more preferably POE sorbitan fatty acid esters, POE hydrogenated castor oil, POE-POP block copolymers; particularly preferably polysorbate 80, polyoxyethylene hydrogenated castor Oil 60, POE-POP block copolymer; more preferably polysorbate 80 is used.

  When a surfactant is added to the SHCL eyedrops of the present invention, the ratio of the surfactant depends on the type of the surfactant, the type and amount of other components, the use of the eyedrop, etc. Can be set as appropriate. As an example of the blending ratio of the surfactant, the total amount of the surfactant is 0.001 to 1.0 w / v%, preferably 0.005 to 0.5 w / v with respect to the total amount of the eye drops for SHCL. %, More preferably 0.01 to 0.1 w / v%.

  The pH of the eye drops for SHCL of the present invention is not particularly limited as long as it is within a range that is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. As an example of the pH of the eye drop for SHCL of the present invention, a range of 4.0 to 9.5, preferably 5.0 to 8.5, and more preferably 5.5 to 8.0 can be mentioned. If the eye drop for SHCL of the present invention is adjusted to be in such a pH range, the effect of suppressing discoloration of SHCL by the component (B) can be more effectively exhibited. Such a pH range is also suitable from the viewpoint of more effectively suppressing the adhesion of corneal epithelial cells to nonionic SHCL.

  Further, the osmotic pressure of the eye drop for SHCL of the present invention is not particularly limited as long as it is within a range acceptable for a living body. As an example of the osmotic pressure ratio of the eye drops for SHCL of the present invention, a range of preferably 0.7 to 5.0, more preferably 0.9 to 3.0, and particularly preferably 1.0 to 2.0 is mentioned. It is done. The osmotic pressure can be adjusted by a method known in the art using inorganic salts, polyhydric alcohols, sugar alcohols, saccharides and the like. The osmotic pressure ratio is the ratio of the osmotic pressure of the sample to the osmotic pressure of 0.9w / v% sodium chloride aqueous solution based on the 15th revised Japanese Pharmacopoeia. Measure with reference to. The standard solution for measuring the osmotic pressure ratio was sodium chloride (Japanese Pharmacopoeia standard reagent) dried at 500-650 ° C for 40-50 minutes, and then allowed to cool in a desiccator (silica gel). Dissolve in water to prepare exactly 100 mL, or use a commercially available standard solution for osmotic pressure ratio measurement (0.9 w / v% sodium chloride aqueous solution).

The eye drop for SHCL of the present invention may contain an appropriate amount of various pharmacologically active components and physiologically active components in addition to the above components as long as the effects of the present invention are not hindered. Such an ingredient is not particularly limited, and examples thereof include an active ingredient in an ophthalmic drug described in the over-the-counter drug manufacturing (import) approval standard 2000 edition (supervised by the Pharmaceutical Affairs Research Committee). Specifically, the following components are listed as components used in ophthalmic drugs.
Antihistamines: for example, iproheptin, diphenhydramine, chlorpheniramine maleate and the like.
Decongestant: Tetrahydrozoline, naphazoline, epinephrine, ephedrine, methylephedrine, etc.
Bactericides: for example, cetylpyridinium, benzalkonium, benzethonium, chlorhexidine, polyhexamethylene biguanide and the like.
Vitamins: flavin adenine dinucleotide sodium, cyanocobalamin, retinol acetate, retinol palmitate, pyridoxine hydrochloride, panthenol, calcium pantothenate, tocopherol acetate, etc.
Anti-inflammatory agents: for example, glycyrrhizic acid, pranoprofen, allantoin, azulene, azulenesulfonic acid, guaiazulene, ε-aminocaproic acid, berberine, lysozyme, licorice and the like.
Astringent: For example, zinc white, zinc lactate, zinc sulfate and the like.
Other: For example, sodium cromoglycate, sodium chondroitin sulfate, sodium hyaluronate, sulfamethoxazole, and salts thereof.

In addition, in the eye drops for SHCL of the present invention, various additives are appropriately selected according to conventional methods according to the use and form as long as they do not impair the effects of the invention, and one or more of them are selected. An appropriate amount may be contained in combination. Examples of such additives include various additives described in Pharmaceutical Additives Encyclopedia 2005 (edited by Japan Pharmaceutical Additives Association). Typical additives include the following additives.
Carrier: An aqueous carrier such as water or hydrous ethanol.
Thickeners: for example, carboxyvinyl polymer, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, alginic acid, polyvinyl alcohol (completely or partially saponified product), polyvinyl pyrrolidone, macrogol, sodium chondroitin sulfate, sodium hyaluronate and the like.
Sugars: for example, glucose, cyclodextrin and the like.
Sugar alcohols: For example, xylitol, sorbitol, mannitol and the like. These may be d-form, l-form or dl-form.
Preservatives, bactericides or antibacterials: for example, alkyldiaminoethylglycine hydrochloride, sodium benzoate, ethanol, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, sorbic acid, potassium sorbate, sodium dehydroacetate, paraoxy Methyl benzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, biguanide compounds (specifically, polyhexamethylene biguanide, etc.), glowul (manufactured by Rhodia) Name) etc.
pH adjusting agent: for example, hydrochloric acid, boric acid, citric acid, acetic acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium hydrogen carbonate, sodium carbonate, borax, triethanolamine, monoethanolamine, Diisopropanolamine, sulfuric acid, phosphoric acid, polyphosphoric acid, propionic acid, oxalic acid, gluconic acid, fumaric acid, lactic acid, tartaric acid, malic acid, succinic acid, gluconolactone, ammonium acetate and the like.
Stabilizer: Dibutylhydroxytoluene, trometamol, sodium formaldehyde sulfoxylate (Longalite), tocopherol, sodium pyrosulfite, monoethanolamine, aluminum monostearate, glyceryl monostearate, etc.
Chelating agents: ethylenediaminediacetic acid (EDDA), ethylenediaminetriacetic acid, ethylenediaminetetraacetic acid (edetic acid, EDTA), N- (2-hydroxyethyl) ethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA), etc.
Perfume or refreshing agent: menthol, anethole, eugenol, camphor, geraniol, cineol, borneol, limonene, ryuno and the like. These may be either d-form, l-form or dl-form, and are formulated as essential oils (mint oil, cool mint oil, spearmint oil, peppermint oil, fennel oil, cinnamon oil, bergamot oil, eucalyptus oil, rose oil, etc.) May be.

  The eye drops for SHCL of the present invention, for example, in an aqueous carrier such as purified water, physiological saline, etc., the desired amount of the above components (A) and (B), and other compounding ingredients as desired at a desired concentration. And prepared according to a conventional method.

  In the eye drop for SHCL of the present invention, the type of SHCL to be applied is not particularly limited, and all SHCL currently marketed or marketed in the future can be applied. In particular, ionic SHCL has a strong tendency to discolor (yellowing) due to the above component (A), but the SHCL eye drops of the present invention effectively discolor even SHCL that is susceptible to discoloration. Can be suppressed. In view of the effects of the present invention, ionic SHCL is suitable as an application target of the eye drop for SHCL of the present invention. In addition, ionicity here means that the ionic component content rate in a contact lens raw material is 1 mol% or more according to the US FDA (US Food and Drug Administration) standard so that those skilled in the art usually understand.

Furthermore, from the viewpoint of more effectively exhibiting the discoloration suppressing effect of the eye drop for SHCL of the present invention, as a suitable example of SHCL to be applied, one or more of the following (i) to (iv), preferably Includes those having all the features (i) to (iv). SHCL having one or more of the following (i) to (iv), especially (i) to (iv), has a tendency to become discolored (yellowing) due to the component (A). According to the SHCL eyedrops of the invention, discoloration due to the component (A) can be effectively suppressed even for such SHCL.
(i) Surface treatment by oxygen plasma treatment.
(ii) The main material constituting SHCL is a copolymer containing at least one silicon-containing monomer selected from the group consisting of a silicon-containing vinyl carbamate monomer and a silicon-containing vinyl carbonate monomer, and a hydrophilic monomer.
(iii) The oxygen permeability is higher than 80 Dk / L, preferably 100 to 120 Dk / L or higher.
(iv) The water content is 20% or more, preferably 30% or more, 90% or less, preferably 60% or less, more preferably 50% or less, and particularly preferably 40% or less.

  In the above (ii), the silicon-containing vinyl carbamate monomer and the silicon-containing vinyl carbonate monomer which are silicon-containing monomers are not particularly limited, but specifically, 1,3-bis [4- Vinyloxycarbonyloxy) but-1-yl] tetramethyl-disiloxane; 3- (trimethylsilyl) propyl vinyl carbonate; 3- (vinyloxycarbonylthio) propyl- [tris (trimethylsiloxy) silane]; tris (trimethylsilo) Shiki) silylpropyl vinyl carbamate (TRISVC); 3- [tris (trimethylsiloxy) silyl] propyl allyl carbamate; 3- [tris (trimethylsiloxy) silyl] propyl vinyl carbonate; t-butyldimethylsiloxyethyl vinyl carbonate And trimethylsilylethyl vinyl carbonate; and trimethylsilylmethyl vinyl carbonate. Among these, Preferably, tris (trimethyl siloxane) silylpropyl vinyl carbamate (TRISVC) is mentioned. These silicon-containing monomers may be used alone or in combination of two or more in the main material copolymer constituting SHCL. Further, the hydrophilic monomer is not particularly limited, but specifically, amide compounds such as N, N-dimethylacrylamide and N, N-dimethylmethacrylamide; cyclic such as N-vinyl-2-pyrrolidone (NVP) (Meth) acrylated (polyalkene glycol) such as polydiethylene glycol containing monomethacrylate, polydiethylene glycol containing dimethacrylate; hydrophilic vinyl carbonate monomers and vinyl carbamate monomers as described in US Pat. No. 5,702,215; Examples include hydrophilic oxazolone monomers described in No. 4910277. Among these, N-vinyl-2-pyrrolidone (NVP) is preferable. These hydrophilic monomers may be used alone or in combination of two or more in the copolymer of the main material constituting SHCL. As a suitable application target of the eye drop for SHCL of the present invention, a main material constituting SHCL is exemplified by a copolymer containing TRISVC and NVP as constituent monomers.

  Further, the oxygen permeability of (iii) above can be measured by a polarographic method according to the description of ISO18369-4: 2006.

  The water content in (iv) above indicates the ratio of water in SHCL, and is specifically determined by the following calculation formula.

Moisture content (%) = (weight of hydrated water / weight of hydrated SHCL) x 100
Such moisture content can be measured by a gravimetric method according to the description of ISO18369-4: 2006.

  Further, as shown in Reference Test Example 3 to be described later, the study of the present inventors has revealed that nonionic SHCL among SHCLs is remarkably easy to adhere to corneal epithelial cells. Furthermore, it has also been clarified by the present inventor that when the component (B) is present alone, adhesion of corneal epithelial cells to nonionic SHCL is promoted. Such a contact lens having high adhesion of corneal cells is obtained from the eye tissue when the contact lens is worn, when the corneal cell adheres to the lens on the cornea and the lens moves or when the lens is removed. May cause damage to the surface of the cornea and pain associated therewith, which may significantly reduce the quality of life (QOL) of the contact lens user. On the other hand, according to the eye drop for SHCL of the present invention, by using the components (A) and (B) in combination, the high corneal cell adhesion of nonionic SHCL can be remarkably suppressed, and the safety is high. Thus, it is possible to wear nonionic SHCL, and the above-mentioned problems peculiar to nonionic SHCL can be solved. In view of this corneal cell adhesion inhibitory effect, non-ionic SHCL can also be mentioned as an example of a suitable application target of the eye drop for SHCL of the present invention. In addition, nonionicity here means that the ionic component content rate in a contact lens material is less than 1 mol% according to the US FDA (US Food and Drug Administration) standard so that those skilled in the art usually understand. . Nonionic SHCL has a tendency that the corneal epithelial cell adhesiveness becomes stronger as the water content becomes 90% or less, further 60% or less, further 50% or less, especially 35% or less, and particularly 35% or less. It becomes remarkable when it becomes. Considering the characteristics of such nonionic SHCL, as an example of a suitable application target that exerts the corneal epithelial cell adhesion inhibitory effect using the SHCL eyedrops of the present invention, among nonionic SHCL, the water content is 35%. The following nonionic SHCL can be mentioned. Since SHCL contains a hydrogel material, it contains at least more than 0% moisture.

The eye drop for SHCL of the present invention can be directly applied to the eye wearing SHCL, and can also be applied to the eye before wearing the SHCL. Since it can also exert an antiallergic action based on the ingredients, it is also useful as an allergy symptom reducing agent. Furthermore, the eye drop for SHCL of the present invention also exhibits an effect of reducing eye strain based on the above component (B), and is therefore useful as an agent for reducing or improving eye strain.

  Conventionally, it has been known that wearing a hard contact lens made of polymethyl methacrylate (PMMA) material tends to cause corneal epithelial disorder (3 o'clock to 9 o'clock staining) due to adhesion of the lens to the cornea. ing. In addition, it is known that even when wearing SCL, a person who has symptoms such as dry eyes (for example, a dry eye patient) tends to damage the cornea due to the lens and tends to cause corneal staining. On the other hand, nonionic SHCL has a property of remarkably adhering to corneal epithelial cells as shown in Reference Test Example 3 to be described later, and furthermore, as an inherent property of SHCL, it is generally harder than ordinary non-silicone SCL. Tend to be physically damaged. In view of the characteristics of such nonionic SHCL, it is apparent that the above-described corneal epithelial disorder is easily caused even by wearing nonionic SHCL. On the other hand, according to the eye drop for SHCL of the present invention, it is possible to effectively suppress the adhesion of corneal epithelial cells to nonionic SHCL, thus preventing corneal epithelial damage caused by wearing nonionic SHCL. be able to. Therefore, the ophthalmic solution for SHCL of the present invention can be used as a preventive agent for corneal epithelial disorder caused by wearing nonionic SHCL, and particularly for those having symptoms of dry eyes (for example, for dry eye patients). Is preferably used.

  In addition, since corneal epithelial cells also have a barrier function against allergens, corneal epithelial disorders caused by non-ionic SHCL wearing as described above decrease the barrier function and cause allergic symptoms of the eyes. There is a fear to make it easier. On the other hand, according to the eye drop for SHCL of the present invention, by suppressing adhesion of corneal epithelial cells to nonionic SHCL, the corneal epithelial cells are maintained in a normal state, and the barrier function of corneal epithelial cells Can be maintained. Therefore, the eye drop for SHCL of the present invention is an eye disease preventive agent (for example, allergic symptom) for a person who uses nonionic SHCL to enhance and prevent various eye diseases including allergic symptoms. It is preferably used as a prophylactic agent).

(II) A method for suppressing the discoloration of SHCL caused by ketotifen and / or a salt thereof, and a method for imparting an action of suppressing the discoloration of SHCL caused by ketotifen and / or a salt thereof to an eye drop As described above, (A) The discoloration (yellowing) of SHCL caused by the component can be suppressed by the component (B).

  Therefore, the present invention, from yet another viewpoint, (A) at least one selected from the group consisting of ketotifen and salts thereof, and (B) at least selected from the group consisting of amino acids, taurine, and salts thereof. Provided is a method for suppressing discoloration of a silicone hydrogel contact lens caused by contacting the component (A), which comprises using one kind of amino acid in combination. The present invention also provides (A) an eye drop for a silicone hydrogel contact lens containing at least one selected from the group consisting of ketotifen and a salt thereof, and (B) a group consisting of an amino acid, taurine, and a salt thereof. A method for imparting to the eye drop an action of suppressing discoloration of a silicone hydrogel contact lens caused by contacting the component (A), comprising blending at least one amino acid selected from Also provide.

  In these methods, the types and blending ratios of components (A) and (B) to be used, the types and blending ratios and content ratios of other ingredients, the types of SHCL that are subject to SHCL eye drops, etc. Is the same as “(I) SHCL eye drops”.

(III) Agent for suppressing discoloration of SHCL caused by ketotifen and / or salt thereof As described above, discoloration (yellowing) of SHCL caused by component (A) can be inhibited by component (B). it can.

  Therefore, the present invention, from yet another viewpoint, comprises (A) ketotifen and a salt thereof, which contains at least one amino acid selected from the group consisting of (B) an amino acid, taurine, and a salt thereof as an active ingredient. An agent for suppressing discoloration of a silicone hydrogel contact lens caused by contacting at least one selected from the group consisting of:

  In the agent, the type of component (B), which is an active ingredient, the usage form of the agent (mixing ratio of component (B)), the SHCL to be applied, the type and content ratio of component (A) causing discoloration, etc. Is the same as “(I) SHCL eye drops”.

(IV) A screening method for a substance capable of suppressing the discoloration of SHCL caused by ketotifen and / or a salt thereof , and as described above, the present inventors said that SHCL discolors (yellowing) by contact with the component (A). New knowledge has been obtained. Therefore, the present invention further provides a method for screening a discoloration inhibitor capable of suppressing discoloration (yellowing) of SHCL caused by contacting at least one selected from the group consisting of ketotifen and a salt thereof. Specifically, this screening method is a method including the following steps (a) to (c):
(a) preparing a test solution containing at least one selected from the group consisting of ketotifen and a salt thereof and a test substance;
(b) contacting the test solution with SHCL and measuring the degree of discoloration (yellowing) of SHCL; and
(c) A screening method comprising the steps of selecting a test solution in which suppression of SHCL discoloration (yellowing) is observed, and selecting a test substance contained in the test solution as the discoloration suppressing substance.

  In this screening method, the test substance is a candidate substance for the above-mentioned discoloration suppressing substance to be used for screening. Moreover, it is desirable that the candidate substance is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable so that the candidate substance can be incorporated into the eye drops for SHCL.

  In the step (a), the test solution is added to an aqueous carrier such as water or a buffer, at least one selected from the group consisting of ketotifen and a salt thereof, for example, 0.01 to 1 w / v%, Furthermore, it is prepared by adding an appropriate amount of a test substance. Here, it is desirable to dilute the test substance in stages and prepare a test solution containing a plurality of concentrations of the test substance.

  In the step (b), the test solution and SHCL are not particularly limited, but the SHCL is immersed in the test solution at 1 to 40 ° C. for about 12 to 24 hours. You can do it. In addition, in the step (b), the degree of discoloration (yellowing) of SHCL may be measured, for example, by qualitatively measuring the degree of discoloration of SHCL, or by using a spectrocolorimeter or color difference meter. May be used to quantitatively measure the degree of discoloration.

  In step (c), in order to select a test solution in which suppression of SHCL discoloration is observed, among the test solutions subjected to screening, the one in which SHCL is not discolored in step (c) or almost all SHCL What is not discolored may be selected. In addition, in this step (c), in order to accurately select a test solution in which suppression of SHCL discoloration is observed, a comparison solution having the same composition as that of the test solution except that the test substance is not contained, and SHCL are the above ( b) The degree of discoloration of SHCL when contacted under the same conditions as in the step may be compared. That is, when the test solution has a lower degree of discoloration than the comparison solution, it can be more accurately determined that the test solution suppresses SHCL discoloration.

  The test substance contained in the test solution thus selected is selected as a substance capable of suppressing the discoloration of SHCL caused by contacting ketotifen and / or a salt thereof (discoloration inhibiting substance).

  The discoloration-suppressing substance obtained by this screening method may be added to SHCL eye drops containing ketotifen and / or its salt in order to suppress discoloration of SHCL that occurs when ketotifen and / or its salt is contacted. it can.

(V) A method for inhibiting adhesion of corneal epithelial cells to nonionic SHCL, a method for providing an eye drop with an inhibitory effect on adhesion of corneal epithelial cells to nonionic SHCL As described above, the component (A) and the component (B) By using the components in combination, adhesion of corneal epithelial cells to nonionic SHCL can be suppressed synergistically.

  Accordingly, the present invention, from yet another point of view, (A) at least one selected from the group consisting of ketotifen and salts thereof and (B) at least one selected from the group consisting of amino acids, taurine and salts thereof Provided is a method for suppressing adhesion of corneal epithelial cells to nonionic SHCL, which comprises contacting an eye drop containing a seed with nonionic SHCL. Further, the present invention provides a nonionic SHCL ophthalmic solution selected from the group consisting of (B) an amino acid, taurine, and a salt thereof together with at least one selected from the group consisting of (A) ketotifen and a salt thereof. There is also provided a method of imparting to the eye drop an action of suppressing adhesion of corneal epithelial cells to nonionic SHCL, characterized by comprising at least one of the above.

  Further, as described above, the component (B) has an action of promoting the adhesion of corneal epithelial cells to nonionic SHCL, and the nonionic SHCL eyedrops containing the component (B) are non- There is a problem that the adhesion of corneal epithelial cells to ionic SHCL is increased. In this way, it is possible to exert a high corneal epithelial cell adhesion inhibitory effect by using the component (A) against the adhesion of corneal epithelial cells to the nonionic SHCL promoted by the component (B). become.

  Accordingly, from yet another aspect, the present invention provides a nonionic SHCL eye drop containing at least one selected from the group consisting of (B) an amino acid, taurine, and salts thereof, (A) ketotifen and There is also provided a method for imparting to the eye drops an action of suppressing adhesion of corneal epithelial cells to nonionic SHCL, which comprises blending at least one selected from the group consisting of the salts.

  In these methods, the types and blending ratios of the components (A) and (B) to be used, the types and blending ratios and content ratios of other components, and nonionics to which the eye drops for nonionic SHCL are applied. The type and the like of sexual SHCL are the same as in the above “(I) SHCL eye drops”.

  EXAMPLES The present invention will be described in detail below based on examples, but the present invention is not limited to these examples.

Reference Test Example 1: Examination of the effect of eye drops containing ketotifen fumarate on the color tone of SCL The following tests were conducted in order to examine the effect of eye drops containing ketotifen fumarate on the color tone of SCL. . The SCL used in this test is a silicone hydrogel contact lens (lens A) and a non-silicone hydrogel contact lens (lens B) shown in Table 1.

  Each 10 ml of the test solution 1 or 2 shown in Table 2 was filled in a glass vial, and each lens shown in Table 1 was immersed and sealed one by one. After shaking for 18 hours under conditions of 34 ° C. and 120 rpm, the lens is pulled up and the moisture on the surface is sufficiently wiped off, and is attached to a white mount so that it is as flat as possible with a transparent tape, and a spectrocolorimeter (CM3500d, Inc.) The color at the center of the lens was measured using Minolta (n = 3). As a control, the color of the unopened product of each lens was measured in the same manner. The color difference (ΔE * ab) between each lens after the test and the control was calculated. Similarly, the lens A was immersed in the test solutions 1 to 4 and the test was performed under the same conditions, and the color difference (ΔE * ab) between the lens A and the control after the test was calculated.

  The results of measuring the color difference (ΔE * ab) between lenses A and B using test solutions 1 and 2 are shown in FIG. Moreover, the result of having measured the color difference ((DELTA) E * ab) of the lens A using the test liquids 1-4 is shown in FIG.

  As is clear from FIG. 1, the lens A, which is SHCL, showed a significantly high color difference (ΔE * ab) when brought into contact with the test solution 2 containing ketotifen fumarate. In particular, the amount of change in b * was large, and it was found that significant yellowing occurred in the lens. This yellowing does not occur in the lens B which is a non-silicone hydrogel lens, and can be said to be a problem peculiar to SHCL. In fact, it was clear that the lens A having a ΔE * ab value of 6 or more had a yellowing that could be clearly recognized with the naked eye, and this was a problem in use. Further, as shown in FIG. 2, when the lens A, which is SHCL, is brought into contact with the test solution 3 or 4 containing ketotifen fumarate as in the case of the test solution 2, yellowing of the lens occurs. Was confirmed.

Reference Test Example 2: Examination of the effect of the buffer in the eye drop containing ketotifen fumarate on the color tone of SHCL To examine the effect of the buffer on the yellowing of SHCL caused by ketotifen fumarate, the lenses shown in Table 1 A test similar to the above Reference Test Example 1 was performed using A (SHCL) and the test solutions shown in Table 3.

  The results are shown in FIG. As is clear from FIG. 3, even when the phosphate buffer was used (test solution 6), the SHCL was yellowed by ketotifen fumarate in the same manner as when the borate buffer (test solutions 2 to 4) was used. Was confirmed to happen. From the above results, it became clear that the yellowing of SHCL by ketotifen fumarate is not affected by the type of buffer.

Test Example 1: SHCL ketotifen fumarate lens A (SHCL) shown in suppressing Table 1 yellowing of Table 4 are shown one by one immersed 34 ° C. Each test solution 10 ml, and shaken for 24 hours at 120rpm conditions (Sample group). In order to measure the amount of ketotifen fumarate adsorbed on a contact lens, 10 ml of each test solution alone (blank group) was also shaken under the same conditions.

  After completion of the shaking, appropriate amounts of the test solution of the sample group and the blank group were collected, and the ketotifen fumarate concentration was quantified by the HPLC method, and the adsorption amount to SHCL was calculated. Further, the lens A immersed in the sample group was subjected to a color difference (ΔE * ab) from the control (lens A which was not opened) by the same method as in Reference Test Example 1 (n = 3).

  The result of measuring the color difference (ΔE * ab) of the lens A is shown in FIG. Table 4 shows the measurement results of the amount of ketotifen fumarate adsorbed per lens A (mg / CL · 24 hrs). As is clear from FIG. 4, SHCL brought into contact with the test solution of Comparative Example 2 has a significantly higher ΔE * ab value than that of Comparative Example 1, and it was found that the lens is yellowed. On the other hand, surprisingly, the SHCL brought into contact with the test solutions of Examples 1 to 4 has a markedly suppressed increase in ΔE * ab compared to the test solution of Comparative Example 2, and the yellowing of SHCL is reduced. It was suppressed. From these results, it became clear that yellowing of SHCL by ketotifen fumarate is effectively suppressed in the presence of ε-aminocaproic acid, taurine, potassium aspartate, or magnesium potassium aspartate.

  In addition, although the possibility of the adsorption of ketotifen fumarate to the lens was considered as a cause of the yellowing of the lens, as shown in Table 4, the adsorption amount of ketotifen fumarate to the lens immersed in each test solution is Since it was comparable, it was confirmed that there was no correlation between the yellowing of SHCL and the adsorption amount of ketotifen fumarate.

Reference Test Example 3: Evaluation of Adhesion of Corneal Epithelial Cells of Various SCLs The following experiment was conducted using five types of SCLs shown in Table 5 to evaluate the adhesion of corneal epithelial cells on the SCL surface. In addition, all SCL used for this test is a commercial item.

Specifically, it was evaluated by the following method. Each SCL was immersed one by one in a 24-well microplate containing 900 μL of growth medium (DMEM medium containing 10% fetal bovine serum) with the convex surface facing upward. In each well, 100 μL of a cell suspension (1 × 10 ⁵ cell / ml) of a rabbit corneal epithelial cell line SIRC (ATCC number: CCL-60) prepared using a growth medium was seeded at 37 ° C., 5 ° C. After culturing for 48 hours under% CO ₂ conditions, the number of viable cells adhered to the soft contact lens was counted. As a control, cells were cultured on the bottom of the microplate without immersing any lens, and the number of viable cells in the wells was counted (control group). In addition, Cell Counting Kit (Dojindo Laboratories) was used for the measurement of the number of viable cells. The ratio of the number of viable cells adhering to the surface of each soft contact lens (ratio of the number of viable cells to the control group;%) was calculated with respect to the total number of viable cells contained in the wells of the control group.

  The obtained results are shown in FIG. As is clear from FIG. 5, the lenses A and B, which are nonionic SHCL, are more prominent than the lens C, which is ionic SHCL, and the lenses D or E, which are non-silicone hydrogel contact lenses. It was confirmed that there was adhesiveness. Further, when the adhesion state of the cells to each SCL was observed with a microscope, cell adhesion was hardly confirmed in the lenses C, D and E, but corneal epithelial cells adhered to the surfaces of the lenses A and B. It was confirmed that From the above results, it was confirmed that nonionic SHCL has significantly higher adhesion of corneal epithelial cells than other types of lenses, and wearing nonionic SHCL has adverse effects such as damage to the corneal surface. It became clear that it could be given.

Test example 2: Adhesion inhibition test of corneal epithelial cells to nonionic SHCL:
Using the test solution shown in Table 6, the adhesion inhibitory effect of corneal epithelial cells on nonionic SHCL was evaluated.

The lens A (nonionic SHCL) shown in Table 5 is immersed one by one in 5 ml of each test solution (Example 5-6 and Comparative Example 3-5) shown in Table 6, and the sample is 24 at 34 ° C. and 120 rpm. Shaking time. After the shaking treatment, the lens A taken out from each test solution is gently washed with physiological saline, and then the moisture is wiped off. It was immersed one by one so as to be on top. In each well, 100 μL of a cell suspension (1 × 10 ⁵ cell / ml) of a rabbit corneal epithelial cell line SIRC (ATCC number: CCL-60) prepared using a growth medium was seeded at 37 ° C., 5 ° C. After culturing for 48 hours under% CO ₂ conditions, the number of viable cells adhered to the lens was counted (sample group). Further, as a control, a lens A (lens A shown in Table 5) which was subjected to the same operation with the control test solution shown in Table 6 instead of the test solution of each Example or Comparative Example was used under the same conditions as above. A cell suspension of a rabbit corneal epithelial cell line was seeded and cultured, and the number of viable cells adhered to the lens A was counted (control group). Furthermore, as a blank, a well containing only 1000 μL of growth medium (DMEM medium containing 10% fetal bovine serum) without seeding rabbit corneal epithelial cells was prepared, and the well was allowed to stand still at 37 ° C. and 5% CO ₂ for 48 hours. (Blank group). In addition, the cell adhesion suppression rate (%) was computed according to the following formula using Cell Counting Kit (Dojindo Laboratories) for the measurement of the number of living cells.

  The obtained result is shown in FIG. As is clear from FIG. 6, ε-aminocaproic acid and aspartic acid itself did not have an inhibitory effect on corneal epithelial cell adhesion, and were found to tend to adhere cells on the contrary (Comparative Example 4- 5). On the other hand, unexpectedly, it was revealed that the cell adhesion inhibition rate against nonionic SHCL can be synergistically increased by using this ε-aminocaproic acid or aspartic acid in combination with ketotifen fumarate ( Example 5-6).

Formulation Examples With the formulation described in Table 7, eye drops for SHCL (Examples 7-18) are prepared.

Claims (3)

  (A) Silicone hydrolyzate containing at least one selected from the group consisting of ketotifen and salts thereof, and (B) at least one amino acid selected from the group consisting of amino acids, taurine, and salts thereof Eye drops for gel contact lenses.   The eye drop for a silicone hydrogel contact lens according to claim 1, comprising ketotifen fumarate as component (A).   The eye drop for a silicone hydrogel contact lens according to claim 1 or 2, comprising as component (B) at least one selected from the group consisting of ε-aminocaproic acid, aspartic acid, taurine, and salts thereof.

Images